Balance Sheet
Accumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GP-Act III Acquisition (GPAT) Common Equity (2023 - 2025)

GP-Act III Acquisition (GPAT) has disclosed Common Equity for 3 consecutive years, with -$14.5 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 3.96% to -$14.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$14.5 million through Dec 2025, down 3.96% year-over-year, with the annual reading at -$14.5 million for FY2025, 3.96% down from the prior year.
  • Common Equity for Q4 2025 was -$14.5 million at GP-Act III Acquisition, down from -$14.4 million in the prior quarter.
  • The five-year high for Common Equity was -$84603.0 in Q1 2023, with the low at -$14.5 million in Q4 2025.
  • Average Common Equity over 3 years is -$8.3 million, with a median of -$13.7 million recorded in 2024.
  • The sharpest move saw Common Equity crashed 15916.27% in 2024, then dropped 3.96% in 2025.
  • GP-Act III Acquisition's Common Equity stood at -$97944.0 in 2023, then plummeted by 14124.54% to -$13.9 million in 2024, then fell by 3.96% to -$14.5 million in 2025.
  • Per Business Quant, the three most recent readings for GPAT's Common Equity are -$14.5 million (Q4 2025), -$14.4 million (Q3 2025), and -$14.3 million (Q2 2025).